»çÀÌÆ®¸Ê
ÀÌ¿ë¾È³»
(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀ̼Ç
Ȩ
Ä«Å×°í¸®
¸ÂÃãÇü½ÃÀåÁ¶»ç
±¹Á¦ÄÁÆÛ·±½º
±Û·Î¹ú ÆÄÆ®³Ê
¸ÞÀϸµ ¼ºñ½º
ȸ»ç¼Ò°³
°æ¿µÀ̳ä
»ç¾÷¿µ¿ª
ÁöÁ¡¾È³»
°í°´»ç ¸ñ·Ï
±Û·Î¹ú ÆÄÆ®³Ê
ÀÌ¿ë¾à°ü
Contact Us
Ȩ
>
±Û·Î¹ú ÆÄÆ®³Ê
>
B
> Biophoenix Limited
A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
Y
Z
Biophoenix Limited
¿µ±¹ ÄÚº¥Æ®¸®¿¡ º»»ç¸¦ µÐ Biophoenix Reports ´Â °Ô³ð, »ý¸í°øÇÐ, ƯÇã, ÀÇ·á IT ±â¼ú µîÀÇ ¹ÙÀÌ¿À ÀÇ·á ºÐ¾ß¸¦ Àü¹®ÀûÀ¸·Î Á¶»çÇÏ´Â ¸®¼Ä¡»çÀÔ´Ï´Ù.
Á¦¸ñ °Ë»ö
1
-
3
¸®ºä (Àüü£º
3
°Ç)
Á¤·Ä
¹ßÇàÀÏ
ÇѱÛÁ¦¸ñ
¿µ¹®Á¦¸ñ
¸®¼Ä¡»ç
°¡°Ý
Ç¥½Ã °Ç¼ö
25
50
100
¹ÙÀÌ¿À½Ã¹Ð·¯¿Í ¹ÙÀÌ¿Àº£Å¸ : »õ·Î¿î ½ÃÀåÀ» ÇâÇÑ Æ÷Áö¼Å´×
Biosimilars and Biobetters: Positioning for a New Market
»óǰÄÚµå :95658
Á¦1, Á¦2 ¼¼´ëÀÇ ¹ÙÀÌ¿À½Ã¹Ð·¯ ½ÃÀå¿¡ ´ëÇØ ºÐ¼®Çϰí Ãâ½Ã ¿Ï·á ¹× °³¹ßÁß¿¡ ÀÖ´Â Çõ½ÅÀû ¹ÙÀÌ¿À½Ã¹Ð·¯ µ¿Çâ, EUÀÇ ±ÔÁ¦, ¹Ì±¹ÀÇ °³¹ß µ¿Çâ, ¼¼°èÀÇ ¹ÙÀÌ¿À½Ã¹Ð·¯ °³¹ß ±â¾÷ 40»ç ÇÁ·ÎÆÄÀÏ ¹× ±¹°¡º° ¿¹Ãø µîÀ» ÀüÇØµå¸³´Ï´Ù.
... ´õº¸±â
°¡°Ý
US $ 1,000
¹ßÇàÀÏ
2009³â 07¿ù
¸®¼Ä¡»ç
Biophoenix Limited
ÆäÀÌÁö¼ö
275 pages
¾ÆÆ÷Åä½Ã½º(Apoptosis) - 2009³â : ¾ÏÀ» ºñ·ÔÇÑ ¿©·¯°¡Áö Áúȯ¿¡¼ÀÇ ±âȸ
Apoptosis 2009: Opportunities in Cancer and Other Diseases
»óǰÄÚµå :95662
148°³ ºÐÀÚÇ¥ÀûÀ» °¡Áø 233°³ ±â¾÷ÀÌ °³¹ßÇÑ 370°³ ¾ÆÆ÷Åä½Ã½º Á¶Á¤ ¾àÁ¦ Èĺ¸¿¡ ´ëÇØ Á¶»ç ºÐ¼®Çϰí, ¾Ï ¹× ±âŸ Áúȯ¿¡¼ÀÇ ½ÃÀå ±âȸ¿¡ ´ëÇØ ÀüÇØµå¸³´Ï´Ù.
... ´õº¸±â
°¡°Ý
US $ 1,000
¹ßÇàÀÏ
2009³â 02¿ù
¸®¼Ä¡»ç
Biophoenix Limited
ÆäÀÌÁö¼ö
310 pages
ÁöÁúÀÌ»óÁõ : ½ÉÇ÷°ü Áúȯ À§Çè °æ°¨ÀÇ ±âȸ
Dyslipidemia: Opportunities in Cardiovascular Risk Reduction
»óǰÄÚµå :95664
ÁöÁúÀÌ»óÁõÀÇ ÇöÀç Ä¡·á¹ý ¹× Ãâ½ÃµÇ¾î ÀÖ´Â Ä¡·áÁ¦, ¸¶ÄÉÆÃ Àü·«, ÀÓ»ó½ÇÇè, ¹ÙÀÌ¿À¸¶Ä¿ µ¿Çâ, 120»ç ÀÌ»ó ±â¾÷ÀÇ 180°³ ¾àÁ¦, ÇâÈÄÀÇ ½ÃÀå °¡´É¼º¿¡ ´ëÇØ ÀüÇØµå¸³´Ï´Ù.
... ´õº¸±â
°¡°Ý
US $ 2,700
¹ßÇàÀÏ
2008³â 08¿ù
¸®¼Ä¡»ç
Biophoenix Limited
ÆäÀÌÁö¼ö
210 pages
»ó±â ÀÚ·á ÀÌ¿ÜÀÇ
Biophoenix Limited
ÀÚ·áµµ ÁÖ¹® °¡´ÉÇÏ´Ï
¹®ÀÇ
ÇÏ¿© Áֽñ⠹ٶø´Ï´Ù.